Korean J Bone Metab.  2011 May;18(1):49-54.

Could Prior Oral-bisphosphonate Administration Reduce the Acute Phase Reaction of Zoledronate?

• Seo SH
• Cho HS
• Cheon SH
• Jeong HM
• Park IH

Abstract

OBJECTIVE
Bisphosphonates are the most commonly prescribed medications for the treatment of osteoporosis. This study was designed to analyze the rate of acute phase reaction (APR) following Zoledronate 5 mg administration in patients with osteoporosis who were treated with prior oral bisphosphonate for at least 2 weeks and to compare naive IV 5 mg Zoledronate.
METHODS
Between July 2009 and October 2010, 27 patients with osteoporosis who were treated with prior oral bisphosphonate for at least 2 weeks, and maximum 52 weeks (average 18.5 weeks) and were between 42-and 85-year-old at the time of study participation. We prospectively evaluated APR, including fever, flu-like symptoms, headache, arthralgia, and myalgia, after 5 mg zoledronate by questionnaire. Additionally we assessed a visual analogue scale (VAS) by 4-point categorical scale.
RESULTS
In this study of 27 patients with osteoporosis, the frequency of APR, flu-like symptom and myalgia were 14.8% and 7.4% and fever, arthralgia, and headache were 3.7% respectively. In VAS, all reactions were mild. The rate of APR rate in this study was statistically decreased compared to previous reports with zoledronate 5 mg IV in bisphosphonate-naive patients.
CONCLUSION
Prior oral bisphosphonate administration for at least 2 weeks could significantly reduce the APR of IV zoledronate 5 mg.

Keyword

Acute phase reaction; Oral bisphosphonate; Zoledronic acid

MeSH Terms

Acute-Phase Reaction
Aged, 80 and over
Arthralgia
Diphosphonates
Fever
Headache
Humans
Imidazoles
Osteoporosis
Prospective Studies
Surveys and Questionnaires
Diphosphonates
Imidazoles